Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease

Interstitial lung disease (ILD) represents a severe pulmonary complication of connective tissue diseases, rheumatoid arthritis (RA), and antineutrophil cytoplasmic antibody-associated vasculitis. Treatment of ILD, mainly based on immunosuppression, remains challenging. Rituximab (RTX), a monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales: Vacchi, Caterina, Manfredi, Andreina, Cassone, Giulia, Erre, Gian Luca, Salvarani, Carlo, Sebastiani, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813433/
https://www.ncbi.nlm.nih.gov/pubmed/33505478
http://dx.doi.org/10.7573/dic.2020-8-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813433/
https://www.ncbi.nlm.nih.gov/pubmed/33505478
http://dx.doi.org/10.7573/dic.2020-8-7

Ejemplares similares